Strontium Effective in Addressing Postmenopausal Osteoporosis

Published: October 10, 2012
Categories:

By both stimulating bone growth while reducing the loss of existing bone material, strontium ranelate has been shown to be able to cause a net increase in bone formation within the human body.

A 2010 review of two large, double-blind, placebo-controlled trials of 5 years' duration showed that strontium was effective in reducing the risk of fractures in women with postmenopausal osteoporosis. Furthermore, patients who continued taking strontium for 3 years after the 5-year trials ended continued to experience protection against new bone fractures and demonstrated additional increased bone density.

Side effects of consuming strontium were minimal, reported by only small numbers of participants as occasional minor nausea or diarrhoea. Some involved in the longer-term therapy also reported minor memory loss.

Reference

"Spotlight on strontium ranelate: in postmenopausal osteoporosis." PubMed.gov, PMID: 20809666 [PubMed - indexed for MEDLINE]

Jacob Teitelbaum, MD

is one of the world's leading integrative medical authorities on fibromyalgia and chronic fatigue. He is the lead author of four research studies on their treatments, and has published numerous health & wellness books, including the bestseller on fibromyalgia and chronic fatigue syndrome From Fatigued to Fantastic! and his newer The Fatigue and Fibromyalgia Solution.  Dr. Teitelbaum is one of the most frequently quoted fibromyalgia experts in the world and appears often as a guest on news and talk shows nationwide including Good Morning America, The Dr. Oz Show, Oprah & Friends, CNN, and Fox News Health. 

e-mail icon
Facebook icon
Twitter icon
Google icon
LinkedIn icon